By Jane Lindborg, Study Director & Research Scientist
RNA-based therapies have moved rapidly from theoretical promise to clinical reality. Today, mRNA, siRNA, antisense oligonucleotides (ASOs), and other RNA modalities are being explored across oncology, rare disease, inflammatory conditions, and beyond.
While these approaches offer powerful advantages—including speed of design and manufacturing—RNA therapeutics also present unique safety challenges. Many of these risks are now well understood, but managing them remains an engineering and translational science problem.
From a preclinical perspective, several recurring safety considerations consistently shape how RNA therapies are evaluated before entering the clinic.
- Immunogenicity Remains a Central Challenge
One of the most common safety risks observed with RNA-based therapies is activation of the immune system. In preclinical models, this often appears as transient stimulation of the innate immune response, which can be detected through real-time clinical pathology assessments.
Common findings include elevated liver enzymes, increased complement activation, and cytokine release. In some cases, immune activation can be severe enough to require immunosuppression regimens, which have become increasingly common in preclinical study designs. When excessive immune responses occur, postmortem and microscopic evaluation frequently confirm immune-mediated pathology as the underlying cause.
Understanding and monitoring immunogenicity early is critical—not only for managing acute toxicity, but also for informing downstream clinical strategies. - Target Specificity and Biodistribution
RNA therapies are highly effective at reaching certain tissues, particularly the liver, where uptake and expression are often robust. While this can be advantageous for hepatic indications, it presents a challenge when the intended target lies elsewhere.
A major risk in RNA-based development is ensuring that the therapy reaches the desired tissue without accumulating in unintended locations. Achieving this balance often requires careful manipulation of RNA chemistry, formulation, and delivery strategy to refine biodistribution while minimizing off-target exposure.
As developers push toward indications involving the heart, lungs, or central nervous system, improving tissue specificity remains a key area of innovation. - RNA Stability, Folding, and Delivery Behavior
Another important consideration is how RNA behaves once introduced into a biological system. RNA structure, folding, and degradation patterns influence not only translation efficiency, but also immune recognition, clearance, and toxicity.
Most clinically advanced RNA therapies rely on non-viral delivery systems, most commonly lipid nanoparticles (LNPs). While LNPs are highly effective at facilitating cellular uptake, they can also contribute to immunogenic responses depending on tissue exposure and formulation characteristics.
Current research efforts are focused on modifying LNP composition and structure—such as incorporating targeting ligands or altering lipid chemistry—to improve controlled release, reduce immune activation, and preserve delivery efficiency. - Organ-Specific Toxicity
Hepatotoxicity and nephrotoxicity remain among the most frequently monitored safety concerns for RNA therapies. These effects are typically assessed in preclinical studies using standard clinical pathology endpoints, including serum chemistry markers for liver and kidney function.
Longitudinal monitoring of body weight, food intake, and overall clinical condition provides additional insight into systemic tolerability. Definitive characterization of toxicity is achieved through postmortem evaluation, where gross and microscopic pathology can reveal how RNA therapies interact with specific organ systems.
This comprehensive preclinical assessment allows sponsors to identify toxicity signals early and refine dosing, formulation, or delivery strategies accordingly. - Variable Efficacy with Non-Viral Delivery Systems
While non-viral delivery systems offer advantages in terms of reduced immunogenicity compared to viral vectors such as adeno-associated viruses (AAVs), they can also result in lower transduction efficiency and less durable protein expression.
In indications where high or sustained expression is required to rescue a critical biological deficit, this reduced efficiency can limit therapeutic effectiveness. These effects are often readily apparent in preclinical models, including transgenic mouse colonies, where early postnatal dosing allows rapid assessment of functional rescue.
Suboptimal dosing or insufficient construct potency may result in failure to achieve the desired biological outcome, underscoring the importance of rigorous preclinical optimization.
Do Safety Risks Differ by RNA Modality?
Across mRNA, siRNA, ASOs, and emerging approaches such as tRNA-based therapies, many safety risks are shared. Immunogenicity, biodistribution, and delivery-related toxicity remain common considerations regardless of modality.
Emerging modalities may carry additional uncertainty simply due to limited preclinical and clinical experience. Systemic administration—most often intravenous—also plays a significant role in risk profiles, as broadly distributed therapies tend to accumulate in the liver and kidneys.
One effective strategy for mitigating both immunogenicity and off-target toxicity is localized delivery. For central nervous system indications, intrathecal administration allows direct targeting of the central nervous system and has demonstrated improved efficacy with minimal immune activation in preclinical models. However, this approach is more invasive and carries procedural risks that must be weighed carefully against systemic delivery.
The Role of Preclinical Research in Risk Mitigation
Many of the safety risks associated with RNA therapeutics are first identified during comprehensive preclinical evaluation. In-life and postmortem studies assess immune activation, biodistribution, organ toxicity, and the development of anti-drug antibodies—factors that may not be evident in vitro.
These findings inform regulatory submissions and guide critical mitigation strategies, including dose optimization, delivery refinement, immunosuppression regimens, and patient selection criteria. Regulatory guidance, such as FDA-recommended immunogenicity risk assessments, relies heavily on this preclinical foundation.
When unexpected toxicity or off-target accumulation is observed, preclinical data provides the opportunity to refine RNA sequence design, structural characteristics, or formulation before advancing to clinical testing.
Looking Ahead
One of the most compelling advantages of RNA therapeutics is the speed with which they can be designed and manufactured compared with traditional small molecules. With core production platforms already established, development efforts increasingly focus on optimizing delivery rather than reinventing the RNA itself.
As computational tools and artificial intelligence continue to evolve, modeling RNA structure–function relationships may further enhance tissue targeting and safety profiles. If applied effectively, these advances could help RNA therapies reach the clinic with increasing speed—while maintaining a strong focus on safety and precision.